EMA In The Clear Over Transparency In COVID-19 Product Assessments
Ombudsman Says Agency Showed ‘High Transparency Standards’
The European Ombudsman has closed an inquiry into the European Medicines Agency’s practices with regard to coronavirus vaccines and treatments.
You may also be interested in...
European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.
Regulatory bodies from Australia, Canada and the UK say a new pilot program will reduce the need for multiple inspections of the same site, while an MoU signed by Australia and Canada will cut the amount of documentary evidence required from drug sponsors seeking GMP clearances.